NYSE:ENFN Enfusion (ENFN) Stock Price, News & Analysis → Top Project Outperforms BTC in 2023… (From Crypto 101 Media) (Ad) Free ENFN Stock Alerts $9.26 +0.03 (+0.33%) (As of 01:05 PM ET) Add Compare Share Share Today's Range$9.22▼$9.3550-Day Range$7.78▼$9.5752-Week Range$7.37▼$11.56Volume98,404 shsAverage Volume408,379 shsMarket Capitalization$1.19 billionP/E Ratio115.76Dividend YieldN/APrice Target$9.33 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Enfusion alerts: Email Address Enfusion MarketRank™ Stock AnalysisAnalyst RatingReduce1.67 Rating ScoreUpside/Downside0.7% Upside$9.33 Price TargetShort InterestBearish6.71% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment-0.04Based on 4 Articles This WeekInsider TradingSelling Shares$54,849 Sold Last QuarterProj. Earnings Growth142.86%From $0.07 to $0.17 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.06 out of 5 starsComputer And Technology Sector494th out of 587 stocksPrepackaged Software Industry179th out of 198 stocks 0.8 Analyst's Opinion Consensus RatingEnfusion has received a consensus rating of Reduce. The company's average rating score is 1.67, and is based on 1 buy rating, 2 hold ratings, and 3 sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $9.33, Enfusion has a forecasted upside of 0.7% from its current price of $9.27.Amount of Analyst CoverageEnfusion has only been the subject of 3 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted6.71% of the float of Enfusion has been sold short.Short Interest Ratio / Days to CoverEnfusion has a short interest ratio ("days to cover") of 7.6.Change versus previous monthShort interest in Enfusion has recently increased by 80.84%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldEnfusion does not currently pay a dividend.Dividend GrowthEnfusion does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ENFN. Previous Next 1.1 News and Social Media Coverage News SentimentEnfusion has a news sentiment score of -0.04. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.58 average news sentiment score of Computer and Technology companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Enfusion this week, compared to 2 articles on an average week.Search InterestOnly 3 people have searched for ENFN on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Enfusion to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Enfusion insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $54,849.00 in company stock.Percentage Held by Insiders39.18% of the stock of Enfusion is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions81.05% of the stock of Enfusion is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 3.1 Earnings and Valuation Earnings GrowthEarnings for Enfusion are expected to grow by 142.86% in the coming year, from $0.07 to $0.17 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Enfusion is 115.89, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 139.13.Price to Earnings Ratio vs. SectorThe P/E ratio of Enfusion is 115.89, which means that it is trading at a less expensive P/E ratio than the Computer and Technology sector average P/E ratio of about 244.68.Price to Earnings Growth RatioEnfusion has a PEG Ratio of 2.65. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioEnfusion has a P/B Ratio of 15.20. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaTop Project Outperforms BTC in 2023…According to a recently published report… One DeFi protocol boasted gains over 100% during one of the biggest crashes the crypto market has ever seen. And now, this crypto coin is set to soar in the parabolic bull run projected in 2024.Just click here for instant access to the #1 Coin for 2024. About Enfusion Stock (NYSE:ENFN)Enfusion, Inc. provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides portfolio management system, which generates a real-time investment book of record that consists of valuation and risk tools that allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and order and execution management system that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines. It also offers accounting/general ledger system, a real-time accounting book of record for chief financial officers, chief operating officers, accountants, and operations teams; Enfusion analytics system, which enables CIOs, portfolio managers, traders, and analysts to analyze portfolios through time horizons and automate customized visualized reports for internal and external stakeholders; and technology-powered and managed services. The company was founded in 1997 and is headquartered in Chicago, Illinois.Read More ENFN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ENFN Stock News HeadlinesMarch 27, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Enfusion, Inc. - ENFNMarch 22, 2024 | markets.businessinsider.comEnfusion’s Growth Strategy Met with Sell Rating Amid Market and Strategic ChallengesMarch 28, 2024 | Crypto 101 Media (Ad)Top Project Outperforms BTC in 2023…According to a recently published report… One DeFi protocol boasted gains over 100% during one of the biggest crashes the crypto market has ever seen. And now, this crypto coin is set to soar in the parabolic bull run projected in 2024.March 21, 2024 | markets.businessinsider.comAnalysts’ Opinions Are Mixed on These Technology Stocks: GoDaddy (GDDY) and Enfusion (ENFN)March 21, 2024 | americanbankingnews.comAnalysts Set Enfusion, Inc. (NYSE:ENFN) PT at $9.33March 20, 2024 | markets.businessinsider.comStifel Nicolaus Keeps Their Buy Rating on Enfusion (ENFN)March 19, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Enfusion, Inc. - ENFNMarch 15, 2024 | markets.businessinsider.comWall Street Favorites: 3 Under-$10 Stocks with Strong Buy Ratings for March 2024March 28, 2024 | Crypto 101 Media (Ad)Top Project Outperforms BTC in 2023…According to a recently published report… One DeFi protocol boasted gains over 100% during one of the biggest crashes the crypto market has ever seen. And now, this crypto coin is set to soar in the parabolic bull run projected in 2024.March 14, 2024 | seekingalpha.comEnfusion, Inc. (ENFN) Q4 2023 Earnings Call TranscriptMarch 14, 2024 | finance.yahoo.comEnfusion, Inc. (NYSE:ENFN) Q4 2023 Earnings Call TranscriptMarch 13, 2024 | markets.businessinsider.comAnalysts Offer Insights on Technology Companies: Copperleaf Tech (OtherCPLFF), Rackspace Technology (RXT) and Enfusion (ENFN)March 12, 2024 | markets.businessinsider.comWilliam Blair Reaffirms Their Buy Rating on Enfusion (ENFN)March 12, 2024 | msn.comEnfusion reports mixed Q4 results; initiates FY24 outlookMarch 12, 2024 | finance.yahoo.comEnfusion Announces Fourth Quarter 2023 Results and Full Year 2023 ResultsMarch 11, 2024 | benzinga.comEarnings Outlook For EnfusionMarch 6, 2024 | benzinga.comMajor Purchase Alert: Oleg Movchan Invests $120K In Enfusion StockFebruary 29, 2024 | msn.comGoldman Sachs Downgrades Enfusion (ENFN)February 28, 2024 | msn.comEnfusion stock retreats after Goldman downgrades to SellFebruary 28, 2024 | markets.businessinsider.comEnfusion Stock Sell Rating: Conservative Revenue Growth and Market Challenges AheadFebruary 20, 2024 | msn.comArteris, Inc. (AIP) Reports Q4 Loss, Tops Revenue EstimatesFebruary 17, 2024 | nasdaq.comEnfusion Breaks Above 200-Day Moving Average - Bullish for ENFNFebruary 13, 2024 | finance.yahoo.comEnfusion Announces Date of Fourth Quarter and Full Year 2023 ResultsFebruary 12, 2024 | finance.yahoo.comEnfusion to Host Investor Day on March 19, 2024February 8, 2024 | bizjournals.comTrust of tech CEO sells Boca Raton mansion for $29 millionJanuary 30, 2024 | realmoney.thestreet.comEnfusion downgraded to Underweight on client risks at JPMorganJanuary 30, 2024 | markets.businessinsider.comJP Morgan Downgrades Enfusion: Here's What You Need To KnowSee More Headlines Receive ENFN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Enfusion and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today3/28/2024Next Earnings (Estimated)5/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorComputer and Technology Industry Prepackaged software Sub-IndustryN/A Current SymbolNYSE:ENFN CUSIPN/A CIK1868912 Webwww.enfusion.com Phone312-253-9800FaxN/AEmployees1,102Year FoundedN/APrice Target and Rating Average Stock Price Target$9.33 High Stock Price Target$11.00 Low Stock Price Target$8.00 Potential Upside/Downside+1.2%Consensus RatingReduce Rating Score (0-4)1.67 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)$0.08 Trailing P/E Ratio115.33 Forward P/E Ratio131.79 P/E Growth2.67Net Income$6.03 million Net Margins3.45% Pretax Margin6.58% Return on Equity10.30% Return on Assets7.78% Debt Debt-to-Equity RatioN/A Current Ratio3.44 Quick Ratio3.44 Sales & Book Value Annual Sales$174.54 million Price / Sales6.77 Cash Flow$0.15 per share Price / Cash Flow63.49 Book Value$0.61 per share Price / Book15.12Miscellaneous Outstanding Shares128,070,000Free Float77,892,000Market Cap$1.18 billion OptionableOptionable Beta0.99 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesMr. Oleg Movchan (Age 49)CEO & Director Comp: $876.34kMr. Bradley Herring (Age 53)Chief Financial Officer Comp: $267.05kMs. Bronwen Bastone (Age 51)Chief People Officer Comp: $566.25kMr. Stephen MalherbeManaging PartnerMr. Neal PawarChief Operating OfficerMs. Valeria Gutowski (Age 42)Chief Accounting Officer Mr. Ignatius Tochukwu NjokuHead of Investor RelationsMatt CampobassoGeneral CounselMr. Joseph DefeoGlobal Head of Managed Services ProductionMr. Jeff YoungHead of ImplementationMore ExecutivesKey CompetitorsHello GroupNASDAQ:MOMOZuoraNYSE:ZUOCouchbaseNASDAQ:BASEPDF SolutionsNASDAQ:PDFSTuyaNYSE:TUYAView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Bought 113,704 shares on 3/11/2024Ownership: 2.825%Wellington Management Group LLPBought 26,464 shares on 3/5/2024Ownership: 0.384%Goldman Sachs Group Inc.Sold 87,922 shares on 3/1/2024Ownership: 0.043%Matthew CampobassoSold 108 sharesTotal: $942.84 ($8.73/share)Valeria GutowskiSold 27 sharesTotal: $235.71 ($8.73/share)View All Insider TransactionsView All Institutional Transactions ENFN Stock Analysis - Frequently Asked Questions Should I buy or sell Enfusion stock right now? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Enfusion in the last year. There are currently 3 sell ratings, 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "reduce" ENFN shares. View ENFN analyst ratings or view top-rated stocks. What is Enfusion's stock price target for 2024? 6 brokerages have issued 1 year price targets for Enfusion's shares. Their ENFN share price targets range from $8.00 to $11.00. On average, they anticipate the company's share price to reach $9.33 in the next twelve months. This suggests a possible upside of 0.7% from the stock's current price. View analysts price targets for ENFN or view top-rated stocks among Wall Street analysts. How have ENFN shares performed in 2024? Enfusion's stock was trading at $9.70 at the start of the year. Since then, ENFN shares have decreased by 4.4% and is now trading at $9.27. View the best growth stocks for 2024 here. Are investors shorting Enfusion? Enfusion saw a increase in short interest during the month of March. As of March 15th, there was short interest totaling 3,020,000 shares, an increase of 80.8% from the February 29th total of 1,670,000 shares. Based on an average daily volume of 395,300 shares, the short-interest ratio is currently 7.6 days. Approximately 6.7% of the shares of the company are sold short. View Enfusion's Short Interest. When is Enfusion's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our ENFN earnings forecast. What guidance has Enfusion issued on next quarter's earnings? Enfusion updated its FY 2024 earnings guidance on Tuesday, March, 12th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $200.0 million-$210.0 million, compared to the consensus revenue estimate of $202.3 million. When did Enfusion IPO? Enfusion (ENFN) raised $300 million in an initial public offering on Thursday, October 21st 2021. The company issued 18,750,000 shares at a price of $15.00-$17.00 per share. Who are Enfusion's major shareholders? Enfusion's stock is owned by a number of institutional and retail investors. Top institutional investors include Brown Capital Management LLC (9.27%), Vanguard Group Inc. (2.83%), Vanguard Group Inc. (2.83%), Wellington Management Group LLP (0.38%), Northern Trust Corp (0.27%) and Charles Schwab Investment Management Inc. (0.23%). Insiders that own company stock include Bradley Herring, Bronwen Bastone, Dan Groman, Deirdre Somers, Hillhouse Investment Managemen, Matthew Campobasso, Oleg Movchan, Roy Luo, Stephen Malherbe, Tarek Hammoud and Valeria Gutowski. View institutional ownership trends. How do I buy shares of Enfusion? Shares of ENFN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSE:ENFN) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersGrab Your Free Bitcoin Today!Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders Alliance“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisorySHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyBuy this small stock before coming AI Tidal WaveChaikin AnalyticsThe 3rd Revolution in WarfareWeiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Enfusion, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.